Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.

Bunney WE Jr, Azarnoff DL, Brown BW Jr, Cancro R, Gibbons RD, Gillin JC, Hullett S, Killam KF, Kupfer DJ, Krystal JH, Stolley PD, French GS, Pope AM.

Arch Gen Psychiatry. 1999 Apr;56(4):349-52. No abstract available.

PMID:
10197830
2.

The risks of pharmacological therapy for insomnia (part 1): update for the clinical nurse specialist.

O'Malley P.

Clin Nurse Spec. 2007 Jul-Aug;21(4):188-90. Review. No abstract available.

PMID:
17622806
3.

Zolpidem: distinct from triazolam?

Lobo BL, Greene WL.

Ann Pharmacother. 1997 May;31(5):625-32. Review.

PMID:
9161660
4.

Comparative clinical profiles of triazolam versus other shorter-acting hypnotics.

Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW.

J Clin Psychiatry. 1992 Dec;53 Suppl:19-31; discussion 32-3. Review.

PMID:
1336776
5.

Insomnia and the new benzodiazepines.

Wincor MZ.

Clin Pharm. 1982 Sep-Oct;1(5):425-32. Review. No abstract available.

PMID:
6135527
6.

Benzodiazepines as a social problem: the case of halcion.

Gabe J.

Subst Use Misuse. 2001 Jul-Aug;36(9-10):1233-59. Review.

PMID:
11592471
7.

The future of drug safety.

Breckenridge A.

Clin Pharmacol Ther. 2007 Feb;81(2):161-3. Review.

PMID:
17259942
8.

Clinical trials of hypnotics.

Rickels K.

J Clin Psychopharmacol. 1983 Apr;3(2):133-9. Review.

PMID:
6132932
9.
10.

Postmarketing surveillance and reporting of adverse drug events.

Baer RK.

S D J Med. 2004 Jan;57(1):13-4. Review. No abstract available.

PMID:
14964975
11.

Zolpidem--a hypnotic with a difference?

[No authors listed]

Drug Ther Bull. 1995 May;33(5):37-9. Review. No abstract available.

PMID:
7587994
12.

Residual effects of hypnotics: epidemiology and clinical implications.

Vermeeren A.

CNS Drugs. 2004;18(5):297-328. Review.

PMID:
15089115
13.

Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics.

Tilson HH, Madre LK, Califf RM.

Clin Pharmacol Ther. 2007 Aug;82(2):118-21. Review.

PMID:
17632533
14.

Issues in the diagnosis and treatment of insomnia.

Dement W, Seidel W, Carskadon M.

Psychopharmacology Suppl. 1984;1:11-43. Review.

PMID:
6382252
15.

An assessment of short-acting hypnotics.

Mendelson WB, Jain B.

Drug Saf. 1995 Oct;13(4):257-70. Review.

PMID:
8573298
16.

Review of triazolam data.

Klett CJ.

J Clin Psychiatry. 1992 Dec;53 Suppl:61-7; discussion 68. Review. No abstract available.

PMID:
1487482
17.

A review of the safety profiles of benzodiazepine hypnotics.

Roth T, Roehrs TA.

J Clin Psychiatry. 1991 Sep;52 Suppl:38-41. Review.

PMID:
1680124
18.

Sleep laboratory studies of hypnotic drugs: efficacy and withdrawal effects.

Kales A, Kales JD.

J Clin Psychopharmacol. 1983 Apr;3(2):140-50. Review.

PMID:
6132933
19.

Rational basis for the use of sleeping pills.

Dement WC.

Pharmacology. 1983;27 Suppl 2:3-38. Review.

PMID:
6366825
20.

Current patterns and future directions in the treatment of insomnia.

Winkelman J, Pies R.

Ann Clin Psychiatry. 2005 Jan-Mar;17(1):31-40. Review.

PMID:
15941029

Supplemental Content

Support Center